There has long been interest as to whether monoamine oxidase type B inhibitors may have disease modifying or neuroprotective benefits in Parkinson’s disease(1-4). Disease modifying agents are thought to alter the course or progression of a particular disease. Neuroprotective therapies alternatively provide protection of neurons from neurodegeneration or other injuries (2-4). No therapies to date have been proven to be disease modifying or neuroprotective in Parkinson’s disease patients.
Parkinson's Today Blog
A common question asked by many patients and families afflicted with Parkinson’s disease is, “what is gene therapy?” Quite simply, gene therapy is placing genetic information (DNA) into the cells and tissues of humans with Parkinson’s disease. In the purest form a defective part of the genome is replaced with a new copy. Perhaps the most interesting part of the evolving story of gene therapy has been the use of a virus as a vector to carry the genetic information into the brain. These viruses have been deactivated and can be safely used for this purpose (1, 2).